Literature DB >> 16880245

Adjuvant trastuzumab with docetaxel or vinorelbine for HER-2-positive breast cancer.

Gianluigi Ferretti, Paola Papaldo, Alessandra Fabi, Paolo Carlini, Alessandra Felici, Francesco Cognetti.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16880245     DOI: 10.1634/theoncologist.11-7-853

Source DB:  PubMed          Journal:  Oncologist        ISSN: 1083-7159


× No keyword cloud information.
  3 in total

1.  Early cardiac toxicity following adjuvant radiotherapy of left-sided breast cancer with or without concurrent trastuzumab.

Authors:  Lu Cao; Gang Cai; Cai Chang; Zhao-Zhi Yang; Yan Feng; Xiao-Li Yu; Jin-Li Ma; Jiong Wu; Xiao-Mao Guo; Jia-Yi Chen
Journal:  Oncotarget       Date:  2016-01-05

2.  External validation of IBTR! 2.0 nomogram for prediction of ipsilateral breast tumor recurrence.

Authors:  Byung Min Lee; Jee Suk Chang; Young Up Cho; Seho Park; Hyung Seok Park; Jee Ye Kim; Joo Hyuk Sohn; Gun Min Kim; Ja Seung Koo; Ki Chang Keum; Chang-Ok Suh; Yong Bae Kim
Journal:  Radiat Oncol J       Date:  2018-06-29

Review 3.  Targeted therapeutic options and future perspectives for HER2-positive breast cancer.

Authors:  Jiani Wang; Binghe Xu
Journal:  Signal Transduct Target Ther       Date:  2019-09-13
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.